Share on LinkedInShare on LinkedIn

ARTICLE · 29 FEBRUARY 2024

When Might A PTAB Rehearing Be Granted?

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

Recently, the Patent Trial and Appeals Board ("PTAB") granted a request for rehearing of a decision that denied an institution of inter partes review and then instituted...

United StatesIntellectual Property

Recently, the Patent Trial and Appeals Board ("PTAB") granted a request for rehearing of a decision that denied an institution of inter partes review and then instituted a trial on all the challenged claims on all the grounds raised by the Petitioner regarding a patent for a cladribine regimen for treating multiple sclerosis. TWi Pharmaceuticals, Inc. v. Merck Serono SA, IPR2023-00049, Paper 15 (December 20, 2023).

Twi Pharmaceuticals (the Petitioner) brought a request for a rehearing of the institution decision denying inter partes review challenging the claims 36, 38, 39, and 41-48 of Merk Serono's (the Patent Owner) U.S. Patent No. 7,713,947 B2 ("the '947 patent"). The basis for the institution was anticipation under 35 U.S.C. § 102(e) by US 7,888,328 B2, issued Feb. 15, 2011 ("Bodor") and obviousness under 35 U.S.C. § 103(a) by Bodor and Rice et al., Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial, NEUROLOGY,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from